Nature Reviews Rheumatology Nature Reviews Rheumatology is a peer-reviewed journal for rheumatologists and affiliated healthcare professionals. The journal delivers timely interpretations of key scientific developments in rheumatology and related areas of study. Nature Reviews Rheumatology is published monthly in print and online and includes news, commissioned commentary and opinion pieces, and comprehensive reviews. Articles are subject to rigorous peerreview and/or review by in-house editors. Topics covered include prevention, diagnosis and treatment of conditions of the joints, muscle, bones, blood vessels and connective tissues, including systemic autoimmune diseases, inflammatory and degenerative joint diseases, regional musculoskeletal disorders, osteoporosis and other metabolic bone diseases, pain management, imaging, immunology, genetics, clinical trials, epidemiology and clinical outcomes. http://feeds.nature.com/nrrheum/rss/current Nature Publishing Group en © 2024 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Nature Reviews Rheumatology © 2024 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. permissions@nature.com Nature Reviews Rheumatology https://www.nature.com/uploads/product/nrrheum/rss.gif http://feeds.nature.com/nrrheum/rss/current <![CDATA[Limitations of the updated EULAR recommendations for osteoarthritis]]> https://www.nature.com/articles/s41584-024-01103-x Nature Reviews Rheumatology, Published online: 18 March 2024; doi:10.1038/s41584-024-01103-x

EULAR’s 2023 updated recommendations for the non-pharmacological treatment of hip and knee osteoarthritis reiterates and confirms, in an abbreviated form, what we have known for more than a decade. Unfortunately, the abbreviated format of the updated recommendations lacks specificity and clinical usefulness. More detailed guidance could have facilitated wider uptake and improved care.]]>
Marius Henriksen doi:10.1038/s41584-024-01103-x Nature Reviews Rheumatology, Published online: 2024-03-18; | doi:10.1038/s41584-024-01103-x 2024-03-18 Nature Reviews Rheumatology 10.1038/s41584-024-01103-x https://www.nature.com/articles/s41584-024-01103-x
<![CDATA[Evidence-Based Guideline for the management of osteoporosis in men]]> https://www.nature.com/articles/s41584-024-01094-9 Nature Reviews Rheumatology, Published online: 14 March 2024; doi:10.1038/s41584-024-01094-9

In this Evidence-Based Guideline article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents recommendations for the diagnosis, monitoring and treatment of osteoporosis in men.]]>
Nicholas R. FuggleCharlotte BeaudartOlivier BruyèreBo AbrahamsenNasser Al-DaghriNansa BurletManju ChandranMario M. RosaBernard CortetCéline DemonceauWillard DerePhilippe HalboutMickaël HiligsmannJohn A. KanisJean-Marc KaufmanAndreas KurthOlivier LamyAndrea LaslopStefania MaggiRadmila MatijevicEugene McCloskeyAli MobasheriMaria C. Prieto YerroRégis P. RadermeckerShaun SabicoYousef Al-SalehStuart SilvermanNicola VeroneseRené RizzoliCyrus CooperJean-Yves ReginsterNicholas C. Harvey doi:10.1038/s41584-024-01094-9 Nature Reviews Rheumatology, Published online: 2024-03-14; | doi:10.1038/s41584-024-01094-9 2024-03-14 Nature Reviews Rheumatology 10.1038/s41584-024-01094-9 https://www.nature.com/articles/s41584-024-01094-9
<![CDATA[The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout]]> https://www.nature.com/articles/s41584-024-01092-x Nature Reviews Rheumatology, Published online: 12 March 2024; doi:10.1038/s41584-024-01092-x

Gout is associated with various cardiometabolic–renal comorbidities that increase the risk of mortality. Sodium–glucose cotransporter type 2 (SGLT2) inhibitors show promise in both addressing the symptoms of gout and managing relevant comorbidities to help prevent premature mortality.]]>
Chio YokoseNatalie McCormickAbhishek AbhishekNicola DalbethTristan PascartFrédéric LiotéAngelo GaffoJohn FitzGeraldRobert TerkeltaubMeghan E. SiseJames L. JanuzziDeborah J. WexlerHyon K. Choi doi:10.1038/s41584-024-01092-x Nature Reviews Rheumatology, Published online: 2024-03-12; | doi:10.1038/s41584-024-01092-x 2024-03-12 Nature Reviews Rheumatology 10.1038/s41584-024-01092-x https://www.nature.com/articles/s41584-024-01092-x
<![CDATA[All fibroblasts are equal, but some are more equal than others]]> https://www.nature.com/articles/s41584-024-01097-6 Nature Reviews Rheumatology, Published online: 11 March 2024; doi:10.1038/s41584-024-01097-6

Characteristic patterns of joint involvement exist in different forms of arthritis. Research now indicates that epigenetic programming of synovial fibroblasts diversifies their response to inflammatory cascades, leading to this anatomical variation in arthritis and its response to treatment.]]>
Chrissy BoltonAdam P. Croft doi:10.1038/s41584-024-01097-6 Nature Reviews Rheumatology, Published online: 2024-03-11; | doi:10.1038/s41584-024-01097-6 2024-03-11 Nature Reviews Rheumatology 10.1038/s41584-024-01097-6 https://www.nature.com/articles/s41584-024-01097-6
<![CDATA[A nosology of immune diseases from deep immunophenotyping]]> https://www.nature.com/articles/s41584-024-01098-5 Nature Reviews Rheumatology, Published online: 11 March 2024; doi:10.1038/s41584-024-01098-5

In 2006, a linear immunological continuum of autoinflammatory and autoimmune disorders ranging from monogenic diseases of innate immunity at one end to monogenic diseases of adaptive immunity at the other end was proposed to classify these conditions. Deep immunophenotyping has now revealed a cell-based nosology of these disorders.]]>
Michael F. McDermott doi:10.1038/s41584-024-01098-5 Nature Reviews Rheumatology, Published online: 2024-03-11; | doi:10.1038/s41584-024-01098-5 2024-03-11 Nature Reviews Rheumatology 10.1038/s41584-024-01098-5 https://www.nature.com/articles/s41584-024-01098-5
<![CDATA[TYK2: an emerging therapeutic target in rheumatic disease]]> https://www.nature.com/articles/s41584-024-01093-w Nature Reviews Rheumatology, Published online: 11 March 2024; doi:10.1038/s41584-024-01093-w

Tyrosine kinase 2 (TYK2), a Janus kinase family member, is involved in immune signalling and is implicated in autoimmune diseases such as systemic lupus erythematosus; inhibitors of TYK2 show promise in treating various diseases and potentially offer advantages over other Janus kinase inhibitors.]]>
Eric MorandJoseph F. MerolaYoshiya TanakaDafna GladmanRoy Fleischmann doi:10.1038/s41584-024-01093-w Nature Reviews Rheumatology, Published online: 2024-03-11; | doi:10.1038/s41584-024-01093-w 2024-03-11 Nature Reviews Rheumatology 10.1038/s41584-024-01093-w https://www.nature.com/articles/s41584-024-01093-w
<![CDATA[APOE in fat pad and synovium contributes to knee OA]]> https://www.nature.com/articles/s41584-024-01099-4 Nature Reviews Rheumatology, Published online: 07 March 2024; doi:10.1038/s41584-024-01099-4

New research has identified apolipoprotein E expressed by fibroblasts and macrophages in the infrapatellar fat pad and synovium as a pathogenetic mediator and potential therapeutic target in knee osteoarthritis.]]>
Robert Phillips doi:10.1038/s41584-024-01099-4 Nature Reviews Rheumatology, Published online: 2024-03-07; | doi:10.1038/s41584-024-01099-4 2024-03-07 Nature Reviews Rheumatology 10.1038/s41584-024-01099-4 https://www.nature.com/articles/s41584-024-01099-4
<![CDATA[Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity]]> https://www.nature.com/articles/s41584-024-01101-z Nature Reviews Rheumatology, Published online: 07 March 2024; doi:10.1038/s41584-024-01101-z

Ribonucleoprotein complexes containing Xist, a long non-coding RNA involved in X chromosome inactivation, are immunogenic and promote autoimmune responses.]]>
Jessica McHugh doi:10.1038/s41584-024-01101-z Nature Reviews Rheumatology, Published online: 2024-03-07; | doi:10.1038/s41584-024-01101-z 2024-03-07 Nature Reviews Rheumatology 10.1038/s41584-024-01101-z https://www.nature.com/articles/s41584-024-01101-z